More than 14 million people suffer from diabetes. The International Diabetes Federation has said if nothing’s done, this figure will reach 34 million by 2040. Africa has the highest percentage of undiagnosed people. At nearly 67%, they’ re at higher risk of developing harmful and costly complications.
GluSense, an Israeli medical device company, is developing Glyde, a miniature injectable, continuous glucose sensor. It’s injected under the skin and transmits Continuous Glucose Monitoring (CGM) values to a wearable device, like a smartwatch, for up to a year. Better quality of life is a big benefit for diabetes patients. It could improve the lives of many Africans.
“Today, diabetic patients need to endure frequent finger pricks daily in order to manage their glucose level, and even with modern CGMs, frequent calibrations, measurement verifications and replacements are still a hassle and limit efficient treatment,” GluSense CEO Dr. Boaz Brill said in an article in mobihealthnews. “In contrast, our Glyde continuous glucose monitor (CGM) will provide accurate glucose measurement for a full year with significantly fewer blood glucose calibrations. This ground-breaking technology will simplify and improve the life of people living with T1D and insulin dependent T2D worldwide.”
There’s more to do for Glyde to attain commercial viability. New funding from the Diabetes Research Fund (DRF) T1D Fund, a recently launched philanthropy dedicated to financing early stage programs for T1D. It’ll help GluSense to launch its first human clinical trial, an important step before it seeks regulatory clearance.
GluSense says it “uses a proprietary fluorescent glucose-sensitive biosensor that ensures accurate glucose measurement across the full physiological range, with enhanced accuracy at the medically important hypo glucose range.” The biosensor’s made of “engineered live cells.” These enable it to replenish itself over a year. It also minimizes the need for less frequent calibrations.
Many CGMs last about a week before they need replacing. Others can last up to 90 days. If GluSense can deliver Glyde with a one year life, it’ll be life changing for many diabetes patients. Its value in Africa could be considerable.